Literature DB >> 25923087

Cytotoxic activity of valproic acid on primary chronic lymphocytic leukemia cells.

Marta Karp1, Kamila Kosior2, Agnieszka Karczmarczyk1, Małgorzata Zając1, Joanna Zaleska1, Waldemar Tomczak2, Sylwia Chocholska2, Marek Hus2, Anna Dmoszyńska2, Krzysztof Giannopoulos3.   

Abstract

BACKGROUND: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in western civilization. The accumulation of CD5+CD19+ B lymphocytes in peripheral blood is due to a defect in the apoptotic pathway rather than excessive proliferation in the bone marrow and lymph nodes. Despite a number of treatments, CLL remains an incurable disease. Valproic acid (VPA) activity, as a histone deacetylase inhibitor, could restore the epigenetic changes underlying the pathogenesis of CLL and thus induce cell death.
OBJECTIVES: In the present study we hypothesized that VPA could induce CLL primary cells death through activation of apoptosis.
MATERIAL AND METHODS: Peripheral blood samples were obtained from 53 CLL patients. Peripheral blood mononuclear cells were isolated through density gradient centrifugation and were the subject of a 24-hour cell culture with 10 mM of VPA. The cytotoxic effect of VPA was evaluated with an XTT test and thereafter confirmed using Annexin V-FITC/PI staining and flow cytometry techniques.
RESULTS: In this study, a median VPA cytotoxicity of 13.88% with a range of 0-54.65% was observed. Annexin V/PI staining confirmed that the demonstrated cytotoxicity was caused by increased apoptosis in the VPA treated cells as compared to control cells. Statistical analysis showed that VPA's effect on CLL cells depends on lactate dehydrogenase serum levels, but is independent of all other prognostic markers.
CONCLUSIONS: The results of the present experiments found that VPA at a clinically applicable concentration significantly induces apoptosis independently of the disease stage and might be a valuable therapeutic agent for all CLL patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25923087     DOI: 10.17219/acem/29264

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  5 in total

Review 1.  Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia.

Authors:  Ying Huang; Jia-Zhu Wu; Jian-Yong Li; Wei Xu
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

2.  Proliferation and apoptosis of T lymphocytes in patients with bipolar disorder.

Authors:  Krzysztof Pietruczuk; Katarzyna A Lisowska; Karol Grabowski; Jerzy Landowski; Jacek M Witkowski
Journal:  Sci Rep       Date:  2018-02-20       Impact factor: 4.379

Review 3.  Molecular Interactions Between Innate and Adaptive Immune Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.

Authors:  Muhammad Haseeb; Muhammad Ayaz Anwar; Sangdun Choi
Journal:  Front Immunol       Date:  2018-11-26       Impact factor: 7.561

4.  Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers.

Authors:  Milena Perez Mak; Fatima Solange Pasini; Lixia Diao; Fabyane O Teixeira Garcia; Tiago Kenji Takahashi; Denyei Nakazato; Renata Eiras Martins; Cristiane Maria Almeida; Marco Aurelio Vamondes Kulcsar; Valdelania Aparecida Lamounier; Emily Montosa Nunes; Isabela Cristina de Souza; Marcio Ricardo Taveira Garcia; Alex Vieira Amadio; Sheila Aparecida C Siqueira; Igor Moysés Longo Snitcovsky; Laura Sichero; Jing Wang; Gilberto de Castro
Journal:  Ecancermedicalscience       Date:  2020-12-15

5.  The Impact of Chlorambucil and Valproic Acid on Cell Viability, Apoptosis and Expression of p21, HDM2, BCL2 and MCL1 Genes in Chronic Lymphocytic Leukemia.

Authors:  Katarzyna Lipska; Agata Filip; Anna Gumieniczek
Journal:  Cells       Date:  2021-05-02       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.